Abstract: Described is a cylindrical secondary battery in which an inner surface of a can is coated to insulate an electrode assembly and a can from each other and to improve heat resistance of the can. The cylindrical secondary battery may include an electrode assembly, a can in which the electrode assembly is accommodated and of which one end is opened so as to be electrically connected to the electrode assembly, a cap plate electrically connected to the electrode assembly, and a rivet terminal insulated from the can and the cap plate, which may be configured to seal one end of the can and which may be insulated from the can. A first coating layer may be provided on at least a portion of an inner surface of the can.

Abstract: Provided is a bioresorbable stent including a stent substrate including a bioresorbable polymer and a contrast medium containing an iodine component, coated on the stent substrate. Since the stent according to the present invention is absorbed in and removed from the human body after a predetermined time, it has excellent biodegradability since it has improved radiopacity by iodine contrast medium coating, it has a high radiography contrast and is very efficient even when a procedure is performed with real time radiography, and since it has low foreshortening and high flexibility, radial force, and re-coil, it may be useful for insertion into a blood vessel having a small diameter, an acute occlusive lesion, an imminent occlusive lesion, and the like.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7×106 cells/mL or more, and of the about 7×106 cells/mL, about 90% or more are CD8+ T cells.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7×106 cells/mL or more, and of the about 7×106 cells/mL, about 90% or more are CD8+ T cells.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7×106 cells/mL or more, and of the about 7×106 cells/mL, about 90% or more are CD8+ T cells.

Abstract: The present invention relates to a method of preparing cancer antigen-specific CD8+ T cells comprising (a) activating the CD8+ T cells from among PBMCs comprising cancer antigen-specific CD8+ T cells, and then expressing a co-stimulatory factor of these CD8+ T cells; (b) selecting the CD8+ T cells expressing a co-stimulatory factor among the cells activated in step (a); (c) increasing the number of CD8+ T cells selected in step (b); (d) freezing the CD8+ T cells obtained in step (c); and (e) thawing the CD8+ T cells that were frozen in step (d).

Abstract: The present invention relates to a method for manufacturing an inner structure of a regenerative cooling type combustion chamber, and more specifically to a method for manufacturing the inner structure of the regenerative cooling type combustion chamber, including the steps of: manufacturing a cylinder structure by performing a vacuum casting process or an air casting process for a copper alloy; manufacturing a circular plate having a constant thickness by forging and rolling the cylinder structure; thermally and mechanically processing the circular plate; spinning the circular plate to manufacture the shape of the regenerative cooling type combustion chamber; and thermally processing the shape of the regenerative cooling type combustion chamber.

Abstract: A telecommunications terminal apparatus and a terminal-stored information updating system and method is disclosed for automatically distributing terminal-stored information and changes made in terminal-stored information among subscribing user's telecommunications terminals. Each telecommunications terminal apparatus includes a memory unit sufficient for storing information, pertaining to at least the subscribing user and one or more other telecommunications terminal apparatus users, such as: concise personal information, detailed personal information, a list of other parties that exchange information with the user, and key information indicative of a level of security or accessibility of information stored therein. Each telecommunications terminal belongs to a group of users handled by a telecommunications subscriber system. More than one subscriber system may be provided to handle multiple groups of users.